Pyrazolecarboxylic acid derivatives, their preparation and pharmaceutical compositions containing them

ABSTRACT

N-Piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide and its salts and solvates are powerful antagonists of the CB 1  cannabinoid receptors. They are prepared by reacting a functional derivative of 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylic acid with 1-aminopiperidine, optionally followed by salification.

[0001] The present invention relates to a novel pyrazole derivative, toits salts and to the solvates thereof, to a process for theirpreparation and to pharmaceutical compositions containing them.

[0002] Patent applications EP-A-576 357, EP-A-658 546 and WO-97/19063describe pyrazole derivatives with affinity for cannabinoid receptors.More particularly, patent appliction EP-A-656 354 describesN-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide,also known as SR 141 716, and the pharmaceutically acceptable saltsthereof which have very good affinity for the central cannabinoidreceptors.

[0003] Compounds similar to SR 141716 have been described in theliterature, in particularN-piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide,referred to hereinbelow as compound A, which is described by B. F.Thomas et al. in J. Pharm. Exp. Therap., 1998, 285, 285-292.

[0004] The effects of cannabinoids are due to an interaction withspecific high-affinity receptors present at the central level (Devane etal., Mol. Pharmacol., 1988, 34, 605-613) and at the peripheral level(Nye et al., Pharmacol. and Experimental Ther., 1985, 234, 784-791;Kaminski et al., 1992, Mol. Pharmacol., 42, 736-742; Munro et al.,Nature, 1993, 365, 61-65).

[0005] Characterization of the receptors was made possible by thedevelopment of synthetic ligands specific for cannabinoid receptors,such as the agonists WIN 55212-2 (J. Pharmacol. Exp. Ther., 1993, 264,1352-1363) or CP 55,940 (J. Pharmacol. Exp. Ther., 1988, 247,1046-1051). The pharmacology of the CB₁ and CB₂ cannabinoid receptorsubtypes is outlined in Pharmacol. Ther., 1997, 74, 129-130.

[0006] A novel N-piperidino-3-pyrazolecarboxamide derivative has nowbeen found which has very good affinity for the CB₁ subtype ofcannabinoid receptors (CB₁ receptors) with long-lasting action, which isuseful in the therapeutic fields in which cannabinoids are known to beinvolved.

[0007] According to one of its aspects, the present invention relates toN-piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide,of formula:

[0008] to its pharmaceutically acceptable salts and to the solvatesthereof.

[0009] According to another of its aspects, the present inventionrelates to a process for preparing compound (I) above, its salts and thesolvates thereof, characterized in that a functional derivative of5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylicacid, of formula:

[0010] is treated with 1-aminopiperidine, in an organic solvent and inthe presence of a base; and the compound thus obtained is optionallyconverted into one of its salts or one of the solvates thereof.

[0011] The reaction is carried out in basic medium, for example in thepresence of triethylamine in an inert solvent such as dichloromethane ortetrahydrofuran.

[0012] Functional derivatives of the acid (II) which may be used are theacid chloride, the anhydride, a mixed anhydride, a C₁-C₄ alkyl ester inwhich the alkyl is straight or branched, an activated ester, for examplethe p-nitrophenyl ester, or the suitably activated free acid, forexample activated with N,N-dicyclohexylcarbodiimide or withbenzotriazole-N-oxotris(dimethylamino)phosphonium (BOP)hexafluorophosphate.

[0013] Thus, by means of the process according to the invention, it ispossible to react the acid chloride of formula (II) obtained by reactingthionyl chloride with the acid of formula (II) in an inert solvent, suchas benzene or toluene, or a chlorinated solvent (for exampledichloromethane, dichloroethane or chloroform), an ether (for exampletetrahydrofuran or dioxane), or an amide (for exampleN,N-dimethylformamide) under an inert atmosphere, at a temperature ofbetween 0° C. and the reflux point of the solvent.

[0014] One variant of the procedure consists in preparing the mixedanhydride of the acid of formula (II) by reacting ethyl chloroformatewith the acid of formula (II), in the presence of a base such astriethylamine.

[0015] The acid of formula (II) can be prepared according to thereaction scheme described below, in which:

[0016] LiHMDS=lithium hexamethyldisilazide

[0017] NBS=N-bromosuccinimide.

[0018] The first step is carried out according to J. Heterocyclic.Chem., 1989, 26, 1389. In the penultimate step, the conversion of the4-bromomethyl substituent of the pyrazole into 4-ethyl is carried outaccording to J. Am. Chem. Soc., 1968, 90, 5615.

[0019] The 1-aminopiperidine used is a commercial product.

[0020] The ester of formula (VII) and the acid of formula (II) can beprepared according to another process which constitutes a furthersubject of the present invention.

[0021] This process is illustrated by the reaction scheme below, inwhich Alk represents a (C₁-C₆)alkyl and represents an ethyl.

[0022] This process is characterized in that an alkyl ester, preferablythe ethyl ester, of5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylicacid is prepared by cyclization of an alkyl ester, preferably the ethylester, of3-(4-bromobenzoyl)-2-(2-(2,4-dichlorophenyl)hydrazono)pentanoic acid(IX).

[0023] This reaction is carried out in a protic solvent such as analcohol, for example a C₁-C₄ alcohol, preferably ethanol, at atemperature of between room temperature and 80° C., preferably inreluxing ethanol.

[0024] According to the invention, the alkyl ester, preferably the ethylester, of3-(4-bromobenzoyl)-2-(2-(2,4-dichlorophenyl)hydrazono)pentanoic acid isprepared by the action of a 2,4-dichlbrophenylhydrazine salt, preferablythe hydrochloride, on an alkyl ester, preferably the ethyl ester, of4-bromobenzoyl-2-oxopentanoic acid (VIII).

[0025] The reaction is carried out in a protic solvent, for example aC₁-C₄ alcohol, preferably ethanol.

[0026] According to the invention, the alkyl ester, preferably the ethylester, of 4-bromobenzoyl-2-oxopentanoic acid is prepared by the actionof LiHMDS and then of an alkyl ester, preferably the ethyl ester, of2-(1-imidazolyl)-2-oxoacetic acid on bromobutyrophenone.

[0027] The reaction is carried out in an organic solvent such as anaromatic solvent or an ether, preferably methyl tert-butyl ether. Thefirst step of this reaction is carried out at low temperature, forexample at a temperature between 0° C. and −60° C., preferably at atemperature in the region of −20° C.; the second step is carried out ata temperature of between room temperature and −20° C., preferably atroom temperature.

[0028] Thus, according to Scheme 2, the preparation of an alkyl ester of5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylicacid (VII) is carried out starting with 4-bromobenzoyl-2-oxopentanoicacid (VIII) by the action of a 2,4-dichlorophenylhydrazine salt,followed by cyclization.

[0029] Bromobutyrophenone is commercially available.

[0030] The ethyl ester of 2-(1-imidazolyl)-2-oxoacetic acid is describedand prepared according to J. Org. Chem., 1981, 46 (1), 211-213.

[0031] The present invention also comprises a process for preparing analkyl ester, preferably the ethyl ester, of5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylicacid, from 4-bromobenzoyl-2-oxopentanoic acid, by the action of a2,4-dichlorophenylhydrazine salt, preferably the hydrochloride, in aprotic solvent, for example a C₁-C₄ alcohol, preferably ethanol. Thereaction is carried out at a temperature of between room temperature and80° C., preferably in reluxing ethanol.

[0032] The compounds of formula:

[0033] in which Alk represents a (C₁-C₆)alkyl are novel and form part ofthe invention. Preferably, Alk represents an ethyl.

[0034] The compound of formula (I) obtained by the process according tothe invention is isolated, in the form of the free base or of a salt orsolvate, according to the conventional techniques.

[0035] The pharmaceutically acceptable salts of the compound of formula(I) comprise the addition salts with acids, such as the hydrochloride,the hydrobromide, the sulphate, the hydrogen sulphate, the dihydrogenphosphate, the methanesulphonate, the methyl sulphate, the oxalate, themaleate, the fumarate, the 2-naphthalenesulphonate, the glyconate, thegluconate, the citrate, the isethionate, the para-toluenesulphonate orthe succinate.

[0036] The compound of formula (I) can be isolated in the form of one ofits salts, for example the hydrochloride or the oxalate; in this case,the free base can be prepared by neutralizing the said salt with aninorganic or organic base, such as sodium hydroxide or ammoniumhydroxide, triethylamine or an alkali metal carbonate or bicarbonatesuch as sodium or potassium carbonate or bicarbonate, and converted intoanother salt such as the methanesulphonate, fumarate or2-naphthalenesulphonate.

[0037] When the compound of formula (I) is obtained in the form of thefree base, the salification is carried out by treatment with the acidchosen in an organic solvent. By treating the free base, dissolved, forexample, in an ether such as diethyl ether or in acetone, with asolution of the acid in the same solvent, the corresponding salt isobtained and is then isolated according to the conventional techniques.

[0038] The compounds of formula (I) have very good in vitro affinity forthe CB₁ cannabinoid receptors, under the experimental conditionsdescribed by Devane et al., Mol. Pharmacol., 1988, 34, 605-613.

[0039] Thus, the compound according to the invention has very strongaffinity for human CB₁ cannabinoid receptors (Ki=5.4 nM) which comparesfavourably with that of SR 141716 for the same receptors, determinedunder the same conditions (Ki=34 nM).

[0040] The compound according to the invention was also compared withN-piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide,(compound A). The affinity of this compound for human CB₁ cannabinoidreceptors, measured under the same conditions, is reflected by a Kivalue of 8 nM.

[0041] Moreover, the duration of occupation of the CB₁ receptors presentin the brain by the 3 compounds below was compared:

[0042] the compound of formula (I) according to the invention,

[0043] SR 141716,

[0044] compound A.

[0045] The study was performed in vivo in mice, after oraladministration of each of the compounds at a dose of 10 mg/kg, accordingto the technique described in M. Rinaldi-Carmona et al., Life Sciences,1995, 56, 1941-1947. The results obtained are collated in the tablebelow. TABLE 1 % of occupation of the receptors 1 hour 24 hours Compoundof 82% 44%  formula (I) SR 141716 69% 4% Compound A 89% 4%

[0046] Surprisingly, it is observed that the compound of formula (I)according to the invention is the only compound which shows appreciableoccupation (44%) 24 hours after its administration.

[0047] Moreover, the antagonist nature of the compound of formula (I)was demonstrated by the results obtained in models of adenylate-cyclaseinhibition as described in M. Rinaldi-Carmona et al., J. Pharmacol. Exp.Ther., 1996, 278, 871-878.

[0048] More particularly, the compound of the present invention, in itsnative form or in the form of one of its pharmaceutically acceptablesalts, is a powerful and selective antagonist of the CB₁ cannabinoidreceptors.

[0049] The antagonist nature of the compound according to the invention,as well as its good penetration into the central nervous system, areconfirmed by the results obtained in the model of antagonism of thehypothermia induced with a cannabinoid receptor agonist. Thus, thecompound of formula (I) according to the invention antagonizes thehypothermia induced with WIN 55212-2 in mice, with an oral ED₅₀ of 0.3mg/kg in the test described by Pertwee R. G. et al. in Marijuana, 84,Ed. Harvey, D. Y. Oxford IRL Press, 1985, 263-277. In this test, theactivity and the duration of action of 3 compounds were compared. Theresults obtained are collated in the table below: TABLE 2 Antagonism ofthe hypothermia induced Duration of action oral ED₅₀ oral dose 24 hCompound of formula (I) 0.3 mg/kg 1 mg/kg active SR 141716 0.4 mg/kg 1mg/kg not active 10 mg/kg  active Compound A 0.3 mg/kg 1 mg/kg notactive 10 mg/kg  active

[0050] It is found that the compound of the present invention has anED₅₀ which is comparable with those of the compounds of the prior art,but its duration of action is markedly longer.

[0051] Thus, whereas 24 hours after their administration, SR 141716 andcompound A are only active at a dose of 10 mg/kg/p.o., the compound offormula (I) according to the invention is active 24 hours after itsadministration, at a dose 10 times lower (1 mg/kg/p.o.).

[0052] The long-lasting action of the compound of formula (I) accordingto the invention is particularly noteworthy and represents an importantadvantage for its use as a medicinal product.

[0053] The toxicity of compounds (I) is compatible with their use asmedicinal products.

[0054] According to another of its aspects, the present inventionrelates to the use of a compound of formula (I), or one of thepharmaceutically acceptable salts or solvates thereof, for thepreparation of medicinal products intended for treating diseasesinvolving the CB₁ cannabinoid receptors.

[0055] For example, and in a non-limiting manner, the compound offormula (I) is useful as a psychotropic medicinal product, in particularfor the treatment of anxiety disorders, mood disorders, deliriumdisorders, psychotic disorders in general, for the treatment ofschizophrenia and depression, as well as for the treatment of disordersassociated with the use of psychotropic substances, in particular in thecase of abuse of a substance and/or dependence on a substance, includingalcohol dependency and nicotine dependency.

[0056] The compound of formula (I) according to the invention can beused as medicinal product for treating neuropathies, migraine, stress,diseases of psychosomatic origin, epilepsy, locomotor disorders, inparticular dyskinesias or Parkinson's disease.

[0057] The compound of formula (I) according to the invention can alsobe used as a medicinal product in the treatment of memory disorders,cognitive disorders, in particular in the treatment of senile dementiaand Alzheimer's disease, as well as in the treatment of attentiondisorders or vigilance disorders. Furthermore, the compound of formula(I) may be useful as a neuroprotective agent, in the treatment ofneurodegenerative diseases.

[0058] The compound of formula (I) according to the invention can beused as a medicinal product in the treatment of appetite disorders,cravings (for sugars, carbohydrates, drugs, alcohol or any appetizingsubstance) and/or eating disorders, in particular as an anorexigenicagent or for the treatment of obesity or bulimia, as well as for thetreatment of type II diabetes or non-insulin-dependent diabetes.Furthermore, the compound of formula (I) according to the invention canbe used as a medicinal product in the treatment of gastrointestinaldisorders, diarrheic disorders, ulcers, vomiting, urinary and bladderdisorders, cardiovascular disorders, fertility disorders, inflammatoryphenomena, infectious diseases and as a medicinal product for anticancerchemotherapy.

[0059] According to the present invention, the compound of formula (I)is most particularly useful for treating psychotic disorders, inparticular schizophrenia; for treating appetite disorders and obesity,for treating for memory and cognitive disorders; for treating alcoholdependency or nicotine dependency, i.e. for withdrawal from alcohol andfor withdrawal from tobacco.

[0060] According to one of its aspects, the present invention relates tothe use of a compound of formula (I), its pharmaceutically acceptablesalts and the solvates thereof for the treatment of the disorders anddiseases indicated above.

[0061] According to another of its aspects, the present invention alsorelates to the use of the compounds of formula (I), in their native formor in radiolabelled form, as a pharmacological tool in man or animals,for detecting and labelling the CB₁ receptors.

[0062] The compound according to the invention is generally administeredas a dosage unit.

[0063] The said dosage units are preferably formulated in pharmaceuticalcompositions in which the active principle is mixed with apharmaceutical excipient.

[0064] Thus, according to another of its aspects, the present inventionrelates to pharmaceutical compositions containing, as active principle,a compound of formula (I), one of its pharmaceutically acceptable saltsor a solvate thereof.

[0065] The compound of formula (I) above and its pharmaceuticallyacceptable salts or solvates can he used at daily doses of from 0.01 to100 mg per kg of body weight of the mammal to be treated, preferably atdaily doses of from 0.02 to 50 mg/kg. In human beings, the dose canpreferably range from 0.05 to 4000 mg per day, more particularly from0.1 to 1000 mg per day depending on the age of the individual to betreated or the type of treatment, i.e. prophylactic or curativetreatment. Although these doses are examples of average situations, itis possible to have special cases in which-higher doses or lower dosesare suitable, and such doses also belong to the invention. According tothe usual practice, the dose which is suitable for each patient isdetermined by the doctor according to the method of administration andthe age, weight and response of the said patient.

[0066] In the pharmaceutical compositions of the present invention fororal, sublingual, inhaled, subcutaneous, intramuscular, intravenous,transdermal, local or rectal administration, the active principle can beadministered in unit administration form, as a mixture with conventionalpharmaceutical supports, to animals and to human beings. The appropriateunit forms of administration comprise oral-route forms such as tablets,gel capsules, powders, granules and oral solutions or suspensions,sublingual and buccal administration forms, aerosols, topicaladministration forms, implants, subcutaneous, intramuscular,intravenous, intranasal or intraocular administration forms and rectaladministration forms.

[0067] In the pharmaceutical compositions of the present invention, theactive principle is generally formulated in dosage units containing from0.05 to 1000 mg, advantageously from 0.1 to 500 mg and preferably from 1to 200 mg, of the said active principle per dosage unit for dailyadministrations.

[0068] When a solid composition is prepared in tablet form, a wettingagent such as sodium lauryl sulphate can be added to the micronized ornon-micronized active principle, and the whole is mixed with apharmaceutical vehicle such as silica, gelatin, starch, lactose,magnesium stearate, talc, gum arabic or the like. The tablets can becoated with sucrose, various polymers or other suitable materials oralternatively they can be treated such that they have sustained ordelayed activity and such that they release a predetermined amount ofactive principle continuously.

[0069] A preparation in gel capsule form is obtained by mixing theactive principle with a diluent such as a glycol or a glycerol ester andby incorporating the mixture obtained into soft or hard gel capsules.

[0070] A preparation in the form of a syrup or elixir can contain theactive principle together with a sweetener, preferably a calorie-freesweetener, methyl paraben and propyl paraben as antiseptic agents, aswell as a flavour enhancer and a suitable colorant.

[0071] The water-dispersible powders or granules can contain the activeprinciple as a mixture with dispersants, wetting agents or suspendingagents, such as polyvinylpyrrolidine, as well as with sweeteners orflavour enhancers.

[0072] For rectal administration, use is made of suppositories which areprepared with binders that melt at the rectal temperature, for examplecocoa butter or polyethylene glycols.

[0073] For parenteral, intranasal or intraocular administration, aqueoussuspensions, isotonic saline solutions or sterile, injectable solutionswhich contain pharmacologically compatible dispersants and/orsolubilizing agents, for example propylene glycol or polyethyleneglycol, are used.

[0074] Thus, to prepare an aqueous solution which can be injectedintravenously, a co-solvent such as, for example, an alcohol, forinstance ethanol or a glycol such as polyethylene glycol or propyleneglycol, and a hydrophilic surfactant such as Tween® 80, can be used. Toprepare an oily solution which can be injected intramuscularly, theactive principle can be dissolved with a triglyceride or a glycerolester.

[0075] Creams, ointments or gels can be used for local administration.

[0076] For transdermal administration, patches in multilayer form orcontaining a reservoir in which the active principle may be in alcoholicsolution can be used.

[0077] For administration by inhalation, an aerosol is used containing,for example, sorbitan trioleate or oleic acid as well astrichlorofluoromethane, dichlorofluoromethane, dichlorotetrafluoroethaneor any other biologically compatible propellent gas; it is also possibleto use a system containing the active principle alone or combined withan excipient, in powder form.

[0078] The active principle can also be formulated in the form ofmicrocapsules-or microspheres, optionally with one or more supports oradditives.

[0079] The active principle can also be in the form of a complex with acyclodextrin, for example α-, β- or γ-cyclodextrin,2-hydroxypropyl-β-cyclodextrin or methyl-β-cyclodextrin.

[0080] Among the forms for sustained release which are useful in thecase of chronic treatments, it is possible to use implants. These can beprepared in the form of an oily suspension or in the form of asuspension of microspheres in an isotonic medium.

[0081] The pharmaceutical compositions of the present invention cancontain, along with the compound of formula (I) or one of itspharmaceutically acceptable salts or solvates, other active principleswhich can be useful in the treatment of the disorders or diseasesindicated above.

[0082] In the present description, the following abbreviations are used:DCM: dichloromethane LiHMDS: lithium hexamethyldisilazide TMSCl:chlorotrimethylsilane PTSA: para-toluenesulphonic acid NBS:N-bromosuccinimide MTBE: methyl tert-butyl ether RT: room temperaturem.p.: melting point TLC: thin layer chromatography NMR: nuclear magneticresonance. The NMR spectra are recorded at 200 MHz in DMSO-d₆ s:singlet; d: doublet; t: triplet; q: quadruplet; m: broad peak ormultiplet; dd: doubled doublet.

[0083] Preparation 1

[0084] Ethyl5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylate

[0085] A) Lithium ethyl4-(4-bromophenyl)-3-methyl-4-oxido-2-oxobutenoate

[0086] 21.6 g of LiHMDS are placed in 340 ml of anhydrous ether undernitrogen and the solution is cooled to −60° C., followed by addition of4 g of bromopropiophenone dissolved in 150 ml of anhydrous ether. Thismixture is allowed to warm to −30° C. and 17.53 ml of ethyl oxalate arethen added. After stirring overnight at RT, the precipitate formed isfiltered off and then rinsed with ether and dried under vacuum. 21.8 gof the expected compound are obtained.

[0087] B) Ethyl4-(4-bromophenyl)-2-[(2,4-dichlorophenyl)-hydrazono]-3-methyl-4-oxobutyrate

[0088] 16.8 g of the compound prepared in the above step and 12.5 g of2,4-dichlorophenylhydrazine hydrochloride in 150 ml of ethanol are mixedtogether and left stirring for 2 and a half hours. The precipitateformed is filtered off, rinsed with ethanol and then dried under vacuum.16.24 g of the expected compound are obtained.

[0089] C) Ethyl5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxylate

[0090] 16.24 g of the compound obtained in the above step are heated for24 hours in 200 ml of acetic acid and the reaction medium is then pouredinto 1 litre of ice-cold water; the precipitate formed is filtered off,rinsed with water and dried under vacuum. 12.8 g of the expectedcompound are obtained, and this product is recrystallized frommethylcyclohexane, m.p.=133° C.

[0091] D) Ethyl4-bromomethyl-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)pyrazole-3-carboxylate

[0092] 12.8 g of the ester obtained in the above step are placed in 130ml of carbon tetrachloride and 5.27 g of N-bromosuccinimide are added,followed by 24 mg of benzoyl peroxide. The mixture is refluxed for 4hours and is then filtered and concentrated under vacuum. The residue ischromatographed on silica, eluting with a toluene/ethyl acetate mixture(97/3; v/v). 7.24 g of the expected compound are obtained, m.p.=116° C.

[0093] E) Ethyl5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylate

[0094] 2.26 g of CuBr are introduced as a suspension in 100 ml of ether,under argon, followed by dropwise addition at −20° C. of a solutioncontaining 20 ml of 1.6 M methyllithium in ether diluted in 20 ml ofether. After stirring for 10 minutes at −20° C., the suspensiondecolorizes and then becomes clear. The resulting mixture is cooled to−78° C. and 7 g of the compound prepared in the above step are added asa solution in 100 ml of ether, over 30 minutes, after which the mixtureis allowed to warm to RT. After stirring for 2 hours, the mixture ishydrolysed by addition of saturated ammonium chloride solution. Theresulting mixture is extracted with ether and washed with water, andthen with saturated NaCl solution. This solution is dried over MgSO₄ andthen evaporated to dryness. The residue is chromatographed on silica,eluting with a toluene/ethyl acetate mixture (96/4; v/v). 3.7 g of theexpected compound are obtained, m.p.=108° C.

[0095] NMR: 1.05 ppm: t: 3H; 1.30 ppm: t: 3H; 2.60 ppm: q: 2H; 4.30 ppm:q: 2H; 7.15 ppm: d: 2H; 7.50-7.75 ppm: m: 5H.

[0096] Prepapation 2

[0097]5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylicacid (II).

[0098] 3.6 g of the ester obtained in Preparation 1 are placed in 54 mlof MeOH and a solution containing 1.08 g of KOH in 6.85 ml of water isadded. The reaction medium is refluxed for 3 hours and then concentratedunder vacuum. The residue is taken up in ice-cold water, acidified topH=1 with 1 N HCl and then extracted with DCM. 3.3 g of the expectedcompound are obtained, m.p.=218° C.

[0099] NMR: 1.10 ppm: t: 3H; 2.70 ppm: q: 2H; 7.25 ppm: d: 2H; 7.60-7.85ppm: m: 5H.

[0100] Preparation 3

[0101] Ethyl 3-(4-bromobenzoyl)-2-oxopentanoate

[0102] A solution of 247 g of 4-bromobutyrophenone in 1500 ml of MTBE isadded to a solution of 210 g of LiHMDS in 2500 ml of MTBE, while keepingthe temperature at −20° C. After stirring for 3 hours at thistemperature, 210 g of ethyl 2-(1-imidazolyl)-2-oxoacetate in 1000 ml ofMTBE are added over 1 hour, at 10° C., and the mixture is left stirringfor 18 hours at room temperature. The lithium salt formed is filteredoff and then suspended in 800 ml of MTBE. 800 ml of 6 N hydrochloricacid are added to the suspension. After separation of the phases bysettling, the ether phase is washed 4 times with 1000 ml of water andthen concentrated under reduced pressure. The expected compound isisolated (263 g). From the NMR analysis, it is a mixture containing 8%of the 4-bromobutyrophenone starting material.

[0103] NMR: 0.86 ppm: t: 3H; 1.10 ppm: t: 3H; 1.83 ppm: mt: 2H; 4.15ppm: q: 2H; 5.19 ppm: t: 1H; 7.70 ppm: d: 2H; 7.98 ppm: d: 2H.

[0104] Preparation 4

[0105] Ethyl5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylate

[0106] A) Ethyl3-(4-bromobenzoyl)-2-(2-(2,4-dichlorophenyl)-hydrazono)pentanoate

[0107] A suspension of 155 g of 2,4-dichlorophenylhydrazinehydrochloride in 1200 ml of ethanol is prepared and 263 g of thecompound of Preparation 3 in 1000 ml of ethanol are added at roomtemperature.

[0108] A small portion of the intermediate formed can be isolated byfiltration and characterized.

[0109] NMR: 0.92 ppm: t: 3H; 1.04 ppm: t: 3H; 1.89 ppm: mt: 2H; 4.16ppm: q: 2H; 4.76 ppm: t: 1H; 7.42 ppm: mt: 2H; 7.60 ppm: s: 1H; 7.75ppm: d: 2H; 7.93 ppm: d: 2H; 12.31 ppm: s: 1H.

[0110] B) Ethyl5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylate

[0111] The suspension obtained is refluxed for 4 hours and then leftstirring for 18 hours at room temperature. The product formed isfiltered off and then dried under vacuum at 50° C. to give the expectedcompound (247 g), m.p.=108° C.

[0112] NMR: 1.07 ppm: t: 3H; 1.28 ppm: t: 3H; 2.58 ppm: q: 2H; 4.32 ppm:q: 2H; 7.16 ppm: d: 2H; 7.53 ppm: dd: 1H; 7.59 ppm: d: 2H; 7.73 ppm:d+small d: 2H.

EXAMPLE1N-Piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide

[0113] A)5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylicAcid Chloride

[0114] 3.2 g of the acid obtained in the above step are placed insuspension in 32 ml of toluene, 1.6 ml of thionyl chloride are added andthe mixture is then refluxed for 3 hours. The reaction medium isconcentrated under vacuum and then taken up in toluene. The operation isrepeated several times. 3.3 g of the expected compound are obtained.

[0115] B)N-Piperidino-5-(4-bromophenyl)-1-(2,4-dichloro-phenyl)-4-ethylpyrazole-3-carboxamide

[0116] A solution of 0.23 ml of N-aminopiperidine and 0.29 ml oftriethylamine in 20 ml of DCM is prepared, under nitrogen, and is cooledto a temperature of between 0° C. and 5° C. 0.8 g of the acid chlorideobtained in the above step in 20 ml of DCM is added. After leavingovernight at RT, the resulting mixture is poured onto ice-cold water andthe phases are separated by settling. The organic phase is extractedwith DCM and then washed with water, with 5% Na₂CO₃ solution and withsaturated NaCl solution. The resulting solution is evaporated to drynessand the residue is then chromatographed on silica, eluting with atoluene/EtOAc mixture (80/20; v/v). 0.52 g of the expected compound isobtained, m.p.=113° C.

[0117] NMR: 1.05 ppm: t: 3H; 1.25-1.65 ppm: m: 6H; 2.65 ppm: q: 2H; 2.80ppm: m: 4H; 7.15 ppm: d: 2H; 7.50-7.80 ppm: m: 5H; 9.10 ppm: s: 1H.

EXAMPLE 2

[0118]N-Piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide

[0119] A)5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylicacid chloride

[0120] A mixture containing 97 g of thionyl chloride and 118 g of thecompound of Preparation 4 in 1200 ml of toluene is prepared and isheated gradually to reflux and is then maintained at reflux for 3 hours.The reaction medium is concentrated.

[0121] B)N-Piperidino-5-(4-bromophenyl)-1-(2,4-dichloro-phenyl)-4-ethylpyrazole-3-carboxamide

[0122] The acid chloride formed is taken up in 380 ml ofmethylcyclohexane and 2.8 g of triethylamine in 218 ml of THF areintroduced. The mixture is kept at 50° C.

[0123] A solution of 30 g of N-aminopiperidine and 28 g of triethylaminein 34 ml of methylcyclohexane is prepared and cooled to 10° C., and themixture containing the acid chloride is added slowly. After stirring for2 hours at 10° C., the product formed is filtered off, taken up in 2000ml of DCM and washed twice with 2000 ml of water. The product isrecrystallized from 4500 ml of methylcyclohexane and then filtered offand dried. 125 g of the expected compound are obtained.

1.N-Piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide,of formula:

its pharmaceutically acceptable salts and the solvates thereof. 2.Process for preparingN-piperidino-5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxamide,its salts and the solvates thereof, characterized in that a functionalderivative of5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylicacid, of formula:

is treated with 1-aminopiperidine, in an organic solvent and in thepresence of a base; and the compound thus obtained is optionallyconverted into one of its salts or one of the solvates thereof. 3.Process according to claim 2, for preparing an alkyl ester of5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylicacid by cyclization of an alkyl ester of3-(4-bromobenzoyl)-2-(2-(2,4-dichlorophenyl)hydrazono)pentanoic acid(IX).
 4. Process according to claim 3, for preparing an alkyl ester of3-(4-bromobenzoyl)-2-(2-(2,4-dichlorophenyl)hydrazono)pentanoic acid bythe action of a 2,4-dichlorophenylhydrazine salt on an alkyl ester of4-bromobenzoyl-2-oxopentanoic acid (VIII).
 5. Process according to claim4, for preparing an alkyl ester of 4-bromobenzoyl-2-oxopentanoic acid bythe action of LiHMDS and then an alkyl ester of2-(1-imidazolyl)-2-oxoacetic acid on bromobutyrophenone.
 6. Processaccording to claim 2, for preparing an alkyl ester of5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethylpyrazole-3-carboxylicacid from 4-bromobenzoyl-2-oxopentanoic acid by the action of a2,4-dichlorophenylhydrazine salt, followed by cyclization.
 7. Compoundof formula:

in which Alk represents a (C₁-C₆)alkyl.
 8. Compound of formula

in which Alk represents a (C₁-C₆)alkyl.
 9. Pharmaceutical compositioncontaining, as active principle, a compound according to claim
 1. 10.Pharmaceutical composition according to claim 9, containing from 0.1 to1000 mg of active principle, in unit dosage form, in which the activeprinciple is mixed with at least one pharmaceutical excipient.
 11. Useof a compound according to claim 1 for the preparation of medicinalproducts intended for treating diseases involving the CB₁ cannabinoidreceptors.
 12. Use of a compound according to claim 11 for the treatmentof psychotic disorders, for the treatment of appetite disorders andobesity, for the treatment of memory and cognitive disorders; for thetreatment of alcohol dependency and for withdrawal from tobacco.